ATRS Antares Pharma Inc.

2.23
+0.14  (7%)
Previous Close 2.09
Open 2.13
Price To book 8.58
Market Cap 348788321
Shares 156,407,319
Volume 5,008,817
Short Ratio 4.30
Av. Daily Volume 2,103,397

SEC filingsSee all SEC filings

  1. 8-K - Current report 171135192
  2. 8-K - Current report 171130622
  3. 8-K - Current report 171025520
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171025367
  5. 8-K - Current report 171016484

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sNDA filing announced April 17, 2017. PDUFA date February 14, 2018. 10-month review despite initial expectations of a 6-month review
Makena - auto injector
Preterm birth
Approved December 8, 2011.
Anturol
Overactive bladder
Approved Oct 14, 2013.
OTREXUP
Rheumatoid arthritis (RA)
PDUFA date October 20, 2017. Noted October 12, 2017 that the FDA has identified deficiencies with the NDA (i.e. likely CRL coming).
XYOSTED (testosterone enanthate)
Testosterone deficiency

Latest News

  1. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Antares Pharma, Inc. - ATRS
  2. Antares Pharma, Inc. – Value Analysis (NASDAQ:ATRS) : October 17, 2017
  3. Vetr Urges Buy On Antares Post-Correction
  4. Antares Pharma, Inc. breached its 50 day moving average in a Bearish Manner : ATRS-US : October 16, 2017
  5. Why Antares Pharma Inc Plummeted Today
  6. Today's Research Reports on Trending Tickers: Antares Pharma and Infinity Pharmaceuticals
  7. Antares Pharma stock plunges more than 30% after FDA letter
  8. Antares Pharma Provides XYOSTED™ Regulatory Update
  9. Corporate News Blog - Antares Pharma Sells ZOMAJET(TM) Assets in a Potential $14.5 Million Deal
  10. Antares Pharma Announces Sale of ZOMAJET™ Needle-Free Delivery System to Ferring Pharmaceuticals
  11. ETFs with exposure to Antares Pharma, Inc. : October 9, 2017
  12. Recent Tech Big-Cap Laggards Finally Gain Some Attention
  13. Biotech Names Flexing Their Muscles
  14. Antares Pharma, Inc. breached its 50 day moving average in a Bullish Manner : ATRS-US : September 27, 2017
  15. ETFs with exposure to Antares Pharma, Inc. : September 26, 2017
  16. Antares Pharma to Present at the Ladenburg Thalmann 2017 Healthcare Conference
  17. Is There Now An Opportunity In Antares Pharma Inc (ATRS)?
  18. Antares: Positive Phase III Trials May Support the Case for Approval of Xyosted
  19. Antares Pharma, Inc. :ATRS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017

SEC Filings

  1. 8-K - Current report 171135192
  2. 8-K - Current report 171130622
  3. 8-K - Current report 171025520
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171025367
  5. 8-K - Current report 171016484
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015185
  7. 8-K - Current report 171013195
  8. 8-K - Current report 17903105
  9. 8-K - Current report 17899345
  10. 8-K - Current report 17897379